Genor Biopharma Holdings Ltd. has provided an update on its proposed merger, which involves the issuance of consideration shares under a specific mandate. The company also mentioned a reverse takeover and a new listing application. Additionally, there are plans for a change of company name and an increase in authorized share capital. The proposal includes the adoption of a one-off share option plan. The transaction is contingent upon certain conditions, including the granting of a whitewash waiver. The merger's finalization remains conditional on meeting these prerequisites.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.